Floatz logo

Epcoritamab

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Izidore Lossos, MDmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 3BBB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 2BB

View all 50 →

Same molecule, other indications

Epcoritamab is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
Small Lymphocytic LymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →